Asosiy kashfiyot: bu gen mutatsiyasi yo'g'on ichak saratoni bilan bog'liq

Ushbu xabarni baham ko'ring

For many years, doctors have been confused about why colon cancer can develop in people who find nothing on colonoscopy. A new discovery from Oklahoma Medical Research may help explain why, and this discovery may detect these cancers earlier and more effectively.

Just behind lung cancer, colon cancer is another leading cause of cancer death in men and women, killing 65,000 Americans every year. If cancer is detected early, the life expectancy will still be greatly improved: the five-year survival rate of people who detect yo'g'on ichak saratoni early is 90%, and the survival rate of patients who are found late is 8%. The most common screening method is colonoscopy, however, during these tests, certain cancer-causing polyps are easily missed.

Doktor Devid Jonsning aytishicha, ba'zi poliplar yo'g'on ichak yuzasiga singib ketgan va odatda tekis va yopiqdir. Bu ularni shifokorlarning topishini qiyinlashtiradi. Kolonoskopiya bilan kasallangan, poliplari bo'lmagan bemorlarda yo'g'on ichak saratoni poliplarni o'z ichiga olmaydigan noma'lum mexanizm orqali rivojlanadi, deb ishoniladi. Endi bu yashirin poliplarning 30% -40% gacha yo'g'on ichak saratoniga aylanishi aniq.

Most cancers and most polyps have more than one mutation, but in these polyps, only one gene called BRAF is mutated. Because these indicator markers can identify polyps, it is possible to create a diagnostic test to analyze a stool sample to find these changes before a colonoscopy. If there are changes, this will be the way doctors know to find hidden polyps. Understanding the downstream effects of BRAF mutations may allow drug intervention to prevent this cascade of DNA changes from occurring completely. Ultimately, this may prevent the development of colon cancer.

Bizning xabarnomamizga obuna bo'ling

Yangilanishlarni oling va Cancerfax blogini hech qachon o'tkazib yubormang

Ko'proq o'rganish uchun

Sitokinlarni ajratish sindromini tushunish: sabablari, belgilari va davolash
CAR T-Cell terapiyasi

Sitokinlarni ajratish sindromini tushunish: sabablari, belgilari va davolash

Sitokinlarni chiqarish sindromi (CRS) - bu immunoterapiya yoki CAR-T hujayra terapiyasi kabi ba'zi davolash usullari bilan qo'zg'atiladigan immunitet tizimining reaktsiyasi. Bu sitokinlarning haddan tashqari chiqarilishini o'z ichiga oladi, bu isitma va charchoqdan tortib organlarning shikastlanishi kabi hayot uchun xavfli asoratlargacha bo'lgan alomatlarni keltirib chiqaradi. Boshqaruv ehtiyotkorlik bilan monitoring va aralashuv strategiyasini talab qiladi.

CAR T Cell terapiyasining muvaffaqiyatida paramediklarning roli
CAR T-Cell terapiyasi

CAR T Cell terapiyasining muvaffaqiyatida paramediklarning roli

Paramediklar davolash jarayonida uzluksiz bemorni parvarish qilishni ta'minlash orqali CAR T-hujayra terapiyasining muvaffaqiyatida hal qiluvchi rol o'ynaydi. Ular tashish paytida hayotiy yordam beradi, bemorlarning hayotiy belgilarini kuzatib boradi va asoratlar paydo bo'lganda shoshilinch tibbiy aralashuvni amalga oshiradi. Ularning tezkor javoblari va mutaxassislarning yordami terapiyaning umumiy xavfsizligi va samaradorligiga hissa qo'shadi, sog'liqni saqlash muassasalari o'rtasida silliq o'tishni osonlashtiradi va ilg'or uyali terapiyaning qiyin manzarasida bemorning natijalarini yaxshilaydi.

Yordam kerak? Bizning jamoamiz sizga yordam berishga tayyor.

Yaqiningiz va yaqinlaringizning tezroq sog'ayib ketishini tilaymiz.

Suhbatni boshlang
Biz onlaynmiz! Biz bilan suhbatlashing!
Kodni skanerlang
Salom,

CancerFax-ga xush kelibsiz!

CancerFax ilg'or bosqich saratoniga duchor bo'lgan shaxslarni CAR T-Cell terapiyasi, TIL terapiyasi va butun dunyo bo'ylab klinik sinovlar kabi ilg'or hujayra terapiyalari bilan bog'lashga bag'ishlangan kashshof platformadir.

Siz uchun nima qilishimiz mumkinligini bizga xabar bering.

1) Chet elda saraton kasalligini davolash?
2) CAR T-hujayrali terapiya
3) Saratonga qarshi emlash
4) Onlayn video konsultatsiya
5) Proton terapiyasi